Angelini Pharma celebrates 40 years of eye healthcare with innovative new solutions for glaucoma side effects
Home News Angelini Pharma celebrates 40 years of eye healthcare with innovative new solutions for glaucoma side effects

Angelini Pharma celebrates 40 years of eye healthcare with innovative new solutions for glaucoma side effects

OCTOBER 3, 2024 BHH Members Initiatives

On the occasion of the centenary Congress of the Spanish Society of Ophthalmology (SEO), BHH member Angelini Pharma has commemorated its 40 years of dedication to ophthalmology, consolidating its firm commitment to innovation in eye health care. Over four decades, the company has worked on developing advanced solutions to improve the quality of life of patients with eye conditions.

To mark this anniversary, Angelini Pharma has announced the launch of a new solution aimed at reducing the side effects of glaucoma treatment, one of the main causes of irreversible blindness worldwide¹.

The relevance of glaucoma in public health

Glaucoma affects more than 3.5% of the population between 40 and 80 years old¹, representing a major public health issue. Despite its high prevalence, early diagnosis remains complex due to the lack of symptoms in the early stages of the disease, leading many patients to discover it when damage to the optic nerve is already significant¹. By the year 2040, it is estimated that 111.8 million people will suffer from glaucoma, reinforcing the urgent need to improve both early detection and treatment options.

In Spain, approximately one million people, that is, 3% of the population, are affected by this disease, although only half of them are aware of their condition due to the lack of initial symptoms.

New approaches in glaucoma treatment

One of the main challenges in glaucoma treatment is adherence to long-term therapy, largely due to associated side effects. Current treatments, focused on reducing intraocular pressure (IOP) to minimize optic nerve damage and preserve the patient's vision³, can cause bothersome symptoms on the ocular surface, such as dryness, stinging, foreign body sensation, burning, or pain⁴. These effects, many caused by medication preservatives or polypharmacy⁵⁻⁸, negatively impact patients' quality of life, decreasing their adherence to treatment and worsening disease progression.

Aware of this reality, Angelini Pharma has dedicated part of its 40 years in ophthalmic health care to developing solutions that minimize these side effects.

Innovation at the service of well-being

Gemma Malla, Director of the Ophthalmology Unit at Angelini Pharma Spain, highlighted the importance of this approach within the company: "At Angelini Pharma, we believe that innovation in ophthalmology has the power to transform patients' lives. Our purpose is to develop solutions that go beyond treating eye diseases, focusing on improving their quality of life and offering them healthier and fuller vision."

In addition to its advances in ophthalmology, Angelini Pharma has also expanded its focus toward key areas such as neurology, recognizing that eye health is closely linked to Brain Health Care. This interconnection between ophthalmology and neurology has led the company to explore new areas of research that address both ocular and neurological disorders, consolidating its position as a leader in comprehensive health care.

The celebration of these 40 years of innovation represents a key milestone for Angelini Pharma, which remains firm in its commitment to embrace science with passion and develop solutions that respond to the most urgent challenges in the field of eye health. With a patient-centered approach and a comprehensive vision of well-being, the company continues advancing in its mission to offer treatments that significantly improve the lives of those who need them.

February 18, 2025 BHH Members Initiatives
FisioReact raises €1M to continue transforming at-home physiotherapy in Spain
The company will use the investment to accelerate its growth across Spain and enhance the patient experience by integrating in-person and online care.
Read more
February 17, 2025 BHH Members Initiatives
INVOX Medical strengthens its leadership in AI adoption for medical documentation
INVOX Medical is advancing its 2025 roadmap with the launch of new solutions to cover all scenarios where healthcare professionals need to document information.
Read more
February 17, 2025 BHH Members Initiatives
How Open Medical has transformed trauma management across an entire region
Discover the Case Study of Open Medical and How they've transformed trauma management across an entire region.
Read more
February 14, 2025 BHH Members Initiatives
Viduet Health achieves highest score for heart failure care in European Union tender TIQUE-PCP
Viduet Health has achieved this highest score for heart failure care in European Union tender TIQUE-PCP, with Hospital de Sant Pau Barcelona patients included early this year.
Read more
February 13, 2025 BHH Members Initiatives
Wearables and AI to improve patient health
Wearables, combined with artificial intelligence, are revolutionizing healthcare. Their integration marks a significant step toward accessible, preventive care focused on improving overall health and well-being.
Read more
February 12, 2025 BHH Members Initiatives
Babel joins forces with SocialDiabetes and Listen.Doctor in a new strategic alliance
This alliance aim to deploy Artificial Intelligence–based models in the healthcare and insurance sectors in Spain, Portugal, Chile, Costa Rica, Colombia, and the United States.
Read more
February 11, 2025 BHH Members Initiatives
Between Technology stands out in 2024 with a 10% sales growth and surpasses 1,000 employees
The technology company increases inclusion in the ICT sector, with women making up 28% of its workforce—exceeding the national and European average.
Read more
February 11, 2025 BHH Members Initiatives
How should health data be defined and used across Europe?
A public consultation is now open to define how health data should be described, made discoverable, accessed and used across all of Europe. 
Read more
February 11, 2025 BHH Members Initiatives
i4KIDS-EUROPE publishes report "Challenges and Opportunities for Effective Paediatric Innovation in Europe"
The report, published by the i4KIDS-EUROPE consortium, examines the state of pediatric innovation and includes recommendations to boost the pediatric and maternal health innovation sector in Europe.
Read more
February 04, 2025 BHH Members Initiatives
Don't miss Kunsen's report on "New Frontiers in Oncological Patient Care"
The report underscores their importance in enabling society to manage resources more efficiently and make them accessible to a broader population.
Read more